insights_auto
Why is FARN down 9.89%?
Dive Deeperchevron_right
FARN:LON
Faron Pharmaceuticals Oy
GBX 25.23
arrow_downward
-9.89%(-2.77) 1D
Nov 19, 4:30:00 PM UTC · GBX
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for FARN...
Open
GBX 26.05
High
GBX 30.00
Low
GBX 25.00
Mkt. cap
52.24M
Avg. vol.
39.85K
Volume
168.19K
52-wk high
GBX 184.36
52-wk low
GBX 25.00
EPS
-GBX 0.10
Shares outstanding
31.03M
No. of employees
36
Open
GBX 26.05
High
GBX 30.00
Low
GBX 25.00
Mkt. cap
52.24M
Avg. vol.
39.85K
Volume
168.19K
52-wk high
GBX 184.36
52-wk low
GBX 25.00
EPS
-GBX 0.10
Shares outstanding
31.03M
No. of employees
36
News stories
From web sources and news partners
ChartMill
·
1 hour ago
S&P 500 Gap Movers: Today's Gap-Up and Gap-Down Stocks
TradingView
·
3 hours ago
Stock Market Today: Dow, S&P 500, Nasdaq 100 Futures Rise as Wall Street Awaits Anthropic’s Listing— PANW, NTES, SLS in Focus (UPDATED)
BigGo Finance
·
6 hours ago
UBS 2027 Outlook: S&P 500 Base Case at 8,200; AI Capex Stall Could Drag It to 5,500
JournalArta
·
31 minutes ago
Joachim Klement to Sell Stocks After S&P 500 Signal
Profile
Faron Pharmaceuticals is a Finnish drug discovery and development company based in Turku, Finland.
The company was founded in 2003 by a group led by Markku Jalkanen, who now acts as the company's Chief Executive Officer. It specialises in the development of treatments for acute organ traumas, vascular damage and cancer immunotherapy.
Its lead product Traumakine has been developed to treat acute respiratory distress syndrome. It is currently undergoing international phase III clinical trials after an open-label, early-phase trial showed promising results in the treatment patients with ARDS. The drug is known to function by enhancing lung CD73 expression and increasing production of anti-inflammatory adenosine, such that vascular leaking and escalation of inflammation are reduced. The U.S. Food and Drug Administration FDA has accepted the proposed protocol design for the next Traumakine study in March 2020. The phase III study is a comparison of efficacy in the treatment of patients with ARDS.
In 2020 Traumakine was selected to take part in the WHO Solidarity trial and REMAP-CAP trials to find drugs for the symptoms of Covid_19. Wikipedia
About Faron Pharmaceuticals Oy
CEOMarkku Jalkanen
Employees36
Founded2003
Headquarters-
SectorHealth Care
IndustryBiotechnology
Websitefaron.com